Latest Distribution Channels News

N1 Holdings reports a steady start to FY26 with a $375,000 net profit and robust cash flow, driven by its SME lending operations and enhanced by AI technology.

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

L1 Group has completed its merger with Platinum Asset Management, forming a $16.9 billion investment powerhouse focused on stabilising funds under management and unlocking significant cost synergies.

Credit Corp Group Limited reported strong earnings growth in 2025, driven by its diversified financial services portfolio and strategic expansion into the UK market, alongside significant advances in AI technology.

Beam Communications reported a robust Q1FY26 with revenue doubling quarter-on-quarter and cash reserves more than doubling, yet ongoing arbitration over its Zoleo divestment casts a shadow on its capital return plans.

BrainChip Holdings has moved its AKD1500 neuromorphic AI chip into volume production, supported by key supply agreements and expanded distribution channels, while maintaining a stable cash position.

Audeara Ltd has reported a remarkable 111% revenue increase in Q1 FY26, driven by strong growth in its technology division and key international partnerships in China and Japan. The company is advancing towards cashflow breakeven with improved cash management and expanding global reach.

MyState Limited’s merger with Auswide Bank has driven a 17% rise in underlying net profit to $41.3 million for FY25, alongside a strengthened capital position and a fully franked 11 cent dividend.

Wide Open Agriculture has developed a novel lupin protein milk formulation that overcomes longstanding technological hurdles, lodging a patent to protect its innovation and gearing up for global commercialisation.

Audeara Limited has landed its maiden purchase order for hearing aid technology in China, marking a pivotal step in its global expansion with production and launch planned for the final quarter of 2025.

ReNerve Limited has achieved its first commercial sales of the EmpliQ™ amniotic tissue products, marking a significant step in its transition from R&D to commercialisation. The EmpliQ™ range complements its existing nerve repair solutions and targets a growing global wound care market.

Medical Developments International reported a strong start to FY26 with significant revenue growth driven by increased Penthrox volumes and pricing improvements in Australia, alongside steady European demand and progress on paediatric label approvals.